Last reviewed · How we verify
NCT06654817
Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Treatment of Pemphigus Vulgaris
trial testing Ofatumumab subcutaneous injection in Pemphigus in 38 participants. Completed in 1 April 2024.
1 April 2024
Quick facts
| Lead sponsor | Chao Ji |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 38 |
| Start date | 1 January 2023 |
| Primary completion | 1 April 2024 |
| Estimated completion | 1 April 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Ofatumumab subcutaneous injection — full drug profile →
Conditions studied
- Pemphigus — all drugs for Pemphigus →
- Pemphigus Vulgaris (PV) — all drugs for Pemphigus Vulgaris (PV) →
Sponsor
Chao Ji — full company profile →
Who can join
Adults 18 to 75, any sex, with Pemphigus or Pemphigus Vulgaris (PV). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A prospective cohort study was conducted, following patients for 36 weeks from January 1, 2023, to April 30, 2024. Patients meeting the diagnostic criteria were nonrandomly grouped based on screening results. The primary endpoints were time to disease control and skin healing. Secondary endpoints included complete remission rates, relapse rates, corticosteroid doses, pemphigus disease area index (PDAI), dermatology life quality index (DLQI), visual analogue scale (VAS) pain scores, CD19+ B cell percentages, desmoglein-specific antibodies, and adverse events.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06654817
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ofatumumab subcutaneous injection
Trials testing the same drug.
- NCT02792218 — Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis · Phase 3 · completed
- NCT02792231 — Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. · Phase 3 · completed
Other recruiting trials for Pemphigus
Currently open trials in the same condition.
- NCT05898308 — Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus · Phase 4 · recruiting
- NCT06454357 — A Clinical Study of B007 in the Treatment of Pemphigus. · Phase 2, PHASE3 · recruiting
- NCT06696716 — ONO-4059 Study in Patients With Steroid-resistant Pemphigus · Phase 3 · recruiting
- NCT04400994 — IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus · Phase 2 · active not recruiting
- NCT05954416 — FARD (RaDiCo Cohort) (RaDiCo-FARD) · recruiting
Other Chao Ji trials
Trials by the same sponsor.
- NCT06663943 — A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313. · Phase 1, PHASE2 · not yet recruiting
- NCT06686082 — A Real-World Study of Biologic Therapy for Subclinical Psoriatic Arthritis · enrolling by invitation
- NCT06561256 — JAK Inhibitors' Efficacy in Bullous Pemphigoid · completed
- NCT06391996 — Biologic Therapy for Generalized Pustular Psoriasis · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06654817 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chao Ji
- Last refreshed: 23 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06654817.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing